Understanding the CAR-T Treatment Process
Panelists discuss which patients are considered for CAR-T therapy in second-line treatment for relapsed/refractory multiple myeloma (R/R MM) (cilta-cel vs ide-cel), describe the specific criteria and institutional guidelines used to determine patient eligibility, and explore how non-medical factors like such as location and financial considerations impact patient selection, while also outlining the typical CAR-T referral process from community physician outreach to patient evaluation and selection.
EP: 1.Exploring CAR-T Therapy in Early Lines of Relapsed/Refractory Multiple Myeloma
EP: 2.Patient Selection and Referral Eligibility for CAR-T Therapy
EP: 3.Understanding the CAR-T Treatment Process
EP: 4.CAR-T Therapy: Approach to Bridging
EP: 5.Care Coordination and Transition Strategies for CAR-T Therapy
EP: 6.CAR-T Therapy in Early Lines of R/R MM: Clinical Scenario Discussion and Key Takeaways
EP: 7.Key Takeaways in CAR-T Therapy for Multiple Myeloma
Video content above is prompted by the following:
- Which patients do you think about consider for CAR-T in second-line treatment for R/R MM (cilta-cel vs ide-cel)?
- Can you describe the specific criteria/institutional guidelines used to determine patient eligibility for CAR-T referral?
- How do non-medical factors (location, money, etc) impact patient selection?
- Walk us through the typical CAR-T referral process at your institution, - from the initial community physician outreach to the patient evaluation and selection.
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
